COMPOUND PROFILE / PROTEINS & BIOLOGICS
Mecasermin / rhIGF-1.
Research draftMecasermin is recombinant human IGF-1 used in a regulated prescription product.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Mecasermin is recombinant human IGF-1 used in a regulated prescription product.
Mechanism
It activates IGF-1 receptors to support growth in a specific deficiency context.
Human research
Clinical evidence and approval concern defined severe IGF-1 deficiency populations, not healthy-user enhancement.
Preclinical & other research
Growth-factor experiments inform pharmacology but do not broaden eligibility.
Safety & unknowns
Hypoglycaemia and growth-related contraindications require the product label.
Regulatory status
US Increlex has a defined indication. It does not validate IGF-1 LR3 or unidentified IGF preparations.
Reported use & evidence
The supplied Mecasermin / rhIGF-1 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.